Charles River Laboratories International, Inc. (CRL) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $165.56 (-0.91%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 14, 2026 | Luke Sergott | Barclays | $210.00 | +26.8% |
| Feb 19, 2026 | Eric Coldwell | Robert W. Baird | $193.00 | +16.6% |
| Feb 19, 2026 | Luke Sergott | Barclays | $200.00 | +20.8% |
| Jan 9, 2026 | Eric Coldwell | Robert W. Baird | $224.00 | +35.3% |
| Jan 9, 2026 | Ann Hynes | Mizuho Securities | $215.00 | +29.9% |
| Dec 1, 2025 | Kallum Titchmarsh | Morgan Stanley | $185.00 | +11.7% |
| Oct 17, 2025 | Ann Hynes | Mizuho Securities | $174.00 | +5.1% |
| Oct 3, 2025 | Elizabeth Anderson | Evercore ISI | $200.00 | +20.8% |
| Oct 2, 2025 | Luke Sergott | Barclays | $195.00 | +17.8% |
| Oct 15, 2024 | Luke Sergott | Barclays | $205.00 | +23.8% |
| Oct 14, 2024 | Jamie Clark | Redburn Partners | $151.00 | -8.8% |
| Sep 17, 2024 | Ann Hynes | Mizuho Securities | $210.00 | +26.8% |
| Aug 8, 2024 | Justin Bowers | Deutsche Bank | $240.00 | +45.0% |
| Jul 10, 2024 | Eric Coldwell | Robert W. Baird | $239.00 | +44.4% |
| Jun 28, 2024 | Luke Sergott | Barclays | $230.00 | +38.9% |
| Jun 6, 2024 | Matthew Sykes | Goldman Sachs | $290.00 | +75.2% |
| May 9, 2024 | Elizabeth Anderson | Evercore ISI | $265.00 | +60.1% |
| Apr 1, 2024 | Elizabeth Anderson | Evercore ISI | $300.00 | +81.2% |
| May 5, 2022 | Donald Hooker | KeyBanc | $300.00 | +81.2% |
| Apr 25, 2022 | David Windley | Jefferies | $280.00 | +69.1% |
Top Analysts Covering CRL
CRL vs Sector & Market
| Metric | CRL | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.41 | 2.24 | 2.41 |
| Analyst Count | 17 | 8 | 18 |
| Target Upside | +24.1% | +1150.2% | +14.9% |
| P/E Ratio | -56.87 | 6.92 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-27 | $3.82B | $3.94B | $4.02B | 9 |
| 2027-03-27 | $948M | $973M | $1.01B | 5 |
| 2027-06-27 | $981M | $1.01B | $1.04B | 5 |
| 2027-09-27 | $988M | $1.01B | $1.05B | 5 |
| 2027-12-27 | $994M | $1.02B | $1.06B | 5 |
| 2028-03-27 | $1.02B | $1.05B | $1.09B | 2 |
| 2028-06-27 | $1.07B | $1.10B | $1.14B | 2 |
| 2028-09-27 | $1.06B | $1.09B | $1.13B | 2 |
| 2028-12-27 | $1.07B | $1.09B | $1.13B | 2 |
| 2029-12-27 | $4.24B | $4.37B | $4.53B | 7 |
| 2030-12-27 | $4.16B | $4.30B | $4.45B | 8 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-27 | $10.89 | $11.08 | $11.23 | 8 |
| 2027-03-27 | $2.46 | $2.54 | $2.66 | 6 |
| 2027-06-27 | $2.92 | $3.02 | $3.17 | 3 |
| 2027-09-27 | $3.13 | $3.24 | $3.39 | 6 |
| 2027-12-27 | $3.25 | $3.36 | $3.53 | 3 |
| 2028-03-27 | $2.89 | $2.99 | $3.13 | 7 |
| 2028-06-27 | $3.39 | $3.50 | $3.67 | 4 |
| 2028-09-27 | $3.32 | $3.43 | $3.60 | 7 |
| 2028-12-27 | $3.38 | $3.49 | $3.66 | 4 |
| 2029-12-27 | $13.45 | $14.01 | $14.67 | 1 |
| 2030-12-27 | $14.77 | $15.39 | $16.12 | 1 |
Frequently Asked Questions
What is the analyst consensus for CRL?
The consensus among 17 analysts covering Charles River Laboratories International, Inc. (CRL) is Buy with an average price target of $202.17.
What is the highest price target for CRL?
The highest price target for CRL is $465.00, set by Daniel Brennan at Cowen & Co. on 2021-08-17.
What is the lowest price target for CRL?
The lowest price target for CRL is $151.00, set by Jamie Clark at Redburn Partners on 2024-10-14.
How many analysts cover CRL?
17 analysts have issued ratings for Charles River Laboratories International, Inc. in the past 12 months.
Is CRL a buy or sell right now?
Based on 17 analyst ratings, CRL has a consensus rating of Buy (2.41/5) with a +24.1% upside to the consensus target of $202.17.
What are the earnings estimates for CRL?
Analysts estimate CRL will report EPS of $11.08 for the period ending 2026-12-27, with revenue estimated at $3.94B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.